Track topics on Twitter Track topics that are important to you
Aberdeen and London, UK – 30 October 2013 – NovaBiotics Ltd, the clinical-stage biotechnology company, today announced that it has partnered with the Cystic Fibrosis Trust and Health Sciences Scotland, for a Phase1/2a clinical trial of its novel compound, Lynovex®.
Lynovex is being developed as a treatment for persistent lung infection in cystic fibrosis (CF). The product works by breaking down excessive mucus and killing the bacteria responsible for recurring infections. It also prevents pathogens establishing long-term, antibiotic resistant infections which are common to people living with CF.
Although in its early stages of development, Lynovex is a drug already approved for oral delivery in an unrelated orphan metabolic disease and has been shown to be safe and well tolerated so has the potential for fast-track clinical development. It has designated orphan drug status in Europe.
Cystic Fibrosis Trust’s support, NovaBiotics is also working in partnership with NHS Grampian and the University of Aberdeen’s CF research team who will undertake initial clinical evaluation and trials of Lynovex.
Deborah O’Neill, CEO of Novabiotics said:
“CF is a life-shortening respiratory disease where the treatments available require a complete re-think. Current options for patients are limited and focus primarily on either the recurrent infections or the over-production of mucus. We believe, with Lynovex, we have a much-needed solution for patients that tackles both of these issues.
“Having the Cystic Fibrosis Trust supporting us is a real boost to our clinical efforts and we are grateful to the Aberdeen CF Patient Group for creating this alliance. With Lynovex, we hope to realise our ambition to improve patients’ lives with an effective, safe, long-term therapy.”
Ed Owen, Chief Executive of the Cystic Fibrosis Trust added:
“Working collaboratively with academics and industry increases our capacity to support transformational research projects to help develop new drugs for people living with cystic fibrosis. We are pleased to be part funding this project and look forward to the results.
“This work forms part of our five year strategy which aims to see the trust engage closely with partners in research and industry, to develop new therapies and treatment, such as Lynovex, to further the quality and length of life of all people with cystic fibrosis.”
Trials will begin in the New Year with results expected at the end of 2014.
- Ends -
Notes to editors
NovaBiotics is developing novel peptide antifungal and antibacterial therapeutics that have the ability to treat a range of poorly served and clinically challenging infections. The mechanism of action of NovaBiotics’ drug candidates minimises or negates the chance of drug resistance developing in the target microbes/infections which they have been designed to treat. NovaBiotics’ antifungal and antibacterials are not toxic to human cells at therapeutic doses unlike many conventional antimicrobial medications. NovaBiotics’ lead clinical programme is Novexatin®. In addition to Novexatin®, the Company is developing Lynovex®, for cystic fibrosis (CF) an antibacterial compound that also breaks down excess mucous produced in the airways of CF patients that is expected to enter a Phase IIa study in Q1 2014; Novamycin®, a peptide antifungal agent against Candida and Aspergillus; Novarifyn®, a peptide antibacterial for difficult to treat multi-drug resistant Gram-negative and Gram-positive infections, including MRSA. Further information is available at www.novabiotics.co.uk.
About the Cystic Fibrosis Trust
About Cystic Fibrosis
Cystic fibrosis is a life-shortening inherited disease, affecting over 10,000 people in the UK and 70,000 Worldwide. Ninety percent of patients are diagnosed before the age of 17 and it is the number one genetic killer of children and young adults. Finding a treatment that can tackle the common infections and resistance that affect and shorten lives is a priority for patients and their families.
For further information please contact:
Dr. Deborah O’Neil - CEO & CSO
Bryan Bodek - Chairman
+44 (0) 1224 711377
Media enquiries (Novabiotics):
Melanie Toyne Sewell / Gemma Howe
Tel: +44 (0) 20 7457 2020
The Cystic Fibrosis Trust
Senior Communications Manager
Cystic Fibrosis Trust
Tel +44 (0) 20 8290 7912
Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...